Por favor, use este identificador para citar o enlazar este ítem: https://repositorio.uca.edu.ar/handle/123456789/9738
Campo DC Valor Lengua/Idioma
dc.contributor.authorCardinali, Daniel Pedroes
dc.date.accessioned2020-04-17T21:58:47Z-
dc.date.available2020-04-17T21:58:47Z-
dc.date.issued2019-
dc.identifier.citationCardinali, D.P. Melatonin as a chronobiotic/cytoprotector : its role in healthy aging [en línea]. Biological Rhythm Research. 2019, 50(1). doi:10.1080/09291016.2018.1491200 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/9738es
dc.identifier.issn0929-1016 (impreso)-
dc.identifier.issn1744-4179 (online)-
dc.identifier.urihttps://repositorio.uca.edu.ar/handle/123456789/9738-
dc.description.abstractAbstract: Preservation of sleep, a proper nutrition and adequate physical exercise are key elements for healthy aging. Aging causes sleep alterations, and in turn, sleep disturbances lead to numerous pathophysiological changes that accelerates the aging process. In the central nervous system, sleep loss impairs the clearance of waste molecules like amyloid-β or tau peptides. Melatonin, a molecule of unusual phylogenetic conservation present in all known aerobic organisms, is effective both as a chronobiotic and a cytoprotective agent to maintain a healthy aging. The late afternoon increase of melatonin “opens the sleep doors” every night and its therapeutic use to preserve slow wave sleep has been demonstrated. Melatonin reverses inflammaging via prevention of insulin resistance, suppression of inflammation and down regulation of proinflammatory cytokines. Melatonin increases the expression of α- and γ-secretase and decreases β-secretase expression. It also inhibits tau phosphorylation. Clinical data support the efficacy of melatonin to treat Alzheimer’s disease, particularly at the early stages of disease. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e. in the 40–100 mg/day range). The potentiality of melatonin as a nutraceutical is discussed.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherTaylor & Francises
dc.rightsAcceso abierto*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.sourceBiological Rhythm Research. 2019, 50(1)es
dc.subjectMELATONINAes
dc.subjectENVEJECIMIENTOes
dc.subjectSUEÑOes
dc.subjectINFLAMACIONes
dc.subjectENFERMEDAD DE ALZHEIMERes
dc.titleMelatonin as a chronobiotic/cytoprotector : its role in healthy aginges
dc.typeArtículoes
dc.identifier.doi10.1080/09291016.2018.1491200-
uca.disciplinaMEDICINAes
uca.issnrd1es
uca.affiliationFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentinaes
uca.affiliationFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentinaes
uca.versionacceptedVersiones
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.languageiso639-1en-
crisitem.author.deptConsejo Nacional de Investigaciones Científicas y Técnicas-
crisitem.author.deptInstituto de Investigaciones Biomédicas - BIOMED-
crisitem.author.deptFacultad de Ciencias Médicas-
crisitem.author.orcid0000-0002-0813-9088-
crisitem.author.parentorgFacultad de Ciencias Médicas-
crisitem.author.parentorgPontificia Universidad Católica Argentina-
Aparece en las colecciones: Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
melatonin-chronobiotic-cytoprotector.pdf374,12 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem

Visualizaciones de página(s)

133
comprobado en 30-abr-2024

Descarga(s)

603
comprobado en 30-abr-2024

Google ScholarTM

Consultar


Altmetric


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons